First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $4M — +2694% growth in a single year.
Why Revenue Could Explode
1Phase I DKT-01 clinical trial data readouts for AML patients - safety, tolerability, and preliminary efficacy signals (complete response rates, minimal residual disease negativity)
2Regulatory milestone achievements - IND approvals for new indications, Fast Track or Orphan Drug designations from FDA/TGA
Watch on earnings: FEDFUNDS - Federal Funds Rate (primary driver of biotech valuation multiples and capital availability), GS10 - 10-Year Treasury Yield (discount rate for long-duration biotech cash flows), BAMLH0A0HYM2 - High Yield Credit Spreads (proxy for risk appetite and speculative asset demand).
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $4M to $7M as phase i dkt-01 clinical trial data readouts for aml patients - safety, tolerability.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.